The value of early second trimester PAPP-A and ADAM12 in screening for pre-eclampsia.
Jonathan P Bestwick, Lynne M George, Tiesheng Wu, Joan K Morris, Nicholas J Wald
Wolfson Institute of Preventive Medicine, Barts and London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ. j.p.bestwick@qmul.ac.uk
Journal of medical screening 2012 MarTo estimate the pre-eclampsia screening performance of PAPP-A (pregnancy-associated plasma protein-A) and ADAM12 (A Disintegrin And Metalloprotease 12) in the early second trimester of pregnancy. Stored frozen serum samples from a previously published nested case-control study comprising 77 women who developed pre-eclampsia and 224 unaffected controls were thawed and assayed for PAPP-A and ADAM12. Levels were converted into multiple of the unaffected median (MoM) values. Neither PAPP-A or ADAM12 were significantly different in women who developed pre-eclamspia compared with unaffected controls (PAPP-A: 0.97 MoM [95% confidence interval 0.73 to 1.25], ADAM12: 1.01 MoM [0.91 to 1.13]). Our results do not support the use of PAPP-A or ADAM12 in early second trimester antenatal screening for pre-eclampsia.
Citation
Jonathan P Bestwick, Lynne M George, Tiesheng Wu, Joan K Morris, Nicholas J Wald. The value of early second trimester PAPP-A and ADAM12 in screening for pre-eclampsia. Journal of medical screening. 2012 Mar;19(1):51-4
Mesh Tags
Substances
PMID: 22357350
View Full Text
